Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3AS,4R,9BR)-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3A,4,9B-hexahydrocyclopenta[c]chromen-8-ol
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the class of 6-hydroxyflavonoids and features a cyclopenta[c]chromene core structure with hydroxy and methoxymethyl substituents[1][2]. It is referenced in chemical databases as an experimental agent but does not have an established clinical use or approved indication. The mechanism of action is not explicitly described in public sources; however—based on its structural similarity to selective estrogen receptor modulators (SERMs) and related chromene derivatives—it may interact with estrogen receptors or related nuclear hormone receptors[1][2]. No information about its pharmacological activity in humans or animals has been published.
- Other names
- (2R,6S,7R)-7-(4-hydroxyphenyl)-10-(methoxymethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien-12-ol(3aS,4R,9bR)-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
02
Targets
ESR1 (ERα)
Beyond the preview
Go deeper on (3AS,4R,9BR)-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3A,4,9B-hexahydrocyclopenta[c]chromen-8-ol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (3AS,4R,9BR)-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3A,4,9B-hexahydrocyclopenta[c]chromen-8-ol.